Patents by Inventor Raymond J. Dattwyler
Raymond J. Dattwyler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10006912Abstract: The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.Type: GrantFiled: December 8, 2014Date of Patent: June 26, 2018Assignee: Biopeptides LLCInventors: Raymond J. Dattwyler, Paul M. Arnaboldi
-
Patent number: 9816991Abstract: The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1-SEQ ID NO:28 and/or SEQ ID NO:41-SEQ ID NO:47, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.Type: GrantFiled: February 1, 2013Date of Patent: November 14, 2017Assignee: BIOPEPTIDES CORPORATIONInventors: Raymond J. Dattwyler, Paul M. Arnaboldi
-
Publication number: 20160313326Abstract: The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.Type: ApplicationFiled: December 8, 2014Publication date: October 27, 2016Applicant: BIOPEPTIDES CORP.Inventors: Raymond J. DATTWYLER, Paul M. ARNABOLDI
-
Publication number: 20160074492Abstract: The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.Type: ApplicationFiled: August 6, 2015Publication date: March 17, 2016Inventors: Raymond J. Dattwyler, Maria Gomes-Solecki
-
Publication number: 20150044256Abstract: The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.Type: ApplicationFiled: August 27, 2014Publication date: February 12, 2015Inventors: Raymond J. Dattwyler, Maria Gomes-Solecki
-
Publication number: 20150017666Abstract: The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1-SEQ ID NO:28 and/or SEQ ID NO:41-SEQ ID NO:47, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.Type: ApplicationFiled: February 1, 2013Publication date: January 15, 2015Inventors: Raymond J. Dattwyler, Paul M. Arnaboldi
-
Patent number: 8821893Abstract: The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.Type: GrantFiled: June 30, 2005Date of Patent: September 2, 2014Assignee: Bio Peptides, Corp.Inventors: Raymond J. Dattwyler, Maria Gomes-Solecki
-
Patent number: 7887815Abstract: The present invention relates, e.g., to an isolated peptide consisting of the sequence MKKDDQIAAAIALRGMA (SEQ ID NO:1) or an active variant thereof, wherein the peptide or active variant can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Also disclosed are linear multimeric peptides that contain the peptide represented by SEQ ID NO:1 as well as one or more additional peptide epitopes from other Borrelia proteins that can also bind specifically to an antibody as above. Compositions and diagnostic kits comprising a peptide of the invention are described, as are diagnostic assays using the peptide(s).Type: GrantFiled: November 10, 2008Date of Patent: February 15, 2011Assignee: Biopeptides CorporationInventors: Raymond J. Dattwyler, Maria Gomes-Solecki
-
Publication number: 20090324638Abstract: The present invention relates, e.g., to a Lactobacillus bacterium, which (1) expresses a recombinant polypeptide containing a lipoprotein signal sequence from the OspA protein of Borrelia burgdorferi, or an active variant of the leader sequence, operably linked to one or more heterologous polypeptide(s) of interest and/or (2) which comprises an expressible polynucleotide encoding a recombinant polypeptide, wherein the polynucleotide encodes a lipoprotein signal from the OspA protein of Borrelia burgdorferi, or an active variant thereof, which is operably linked to one or more heterologous polypeptide(s) of interest. In one embodiment, the heterologous polypeptide is from Yersinia pestis, the etiologic agent of plague. In another embodiment, the heterologous polypeptide is from Borrelia burgdorferi, the etiologic agent of Lyme disease.Type: ApplicationFiled: June 12, 2006Publication date: December 31, 2009Applicants: Biopeptides Corp., Lactrys Octrooi BVInventors: Raymond J. Dattwyler, Maria J.C. Gomes-Solecki, Jozef F.M.L. Seegers
-
Publication number: 20090297560Abstract: The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.Type: ApplicationFiled: June 30, 2005Publication date: December 3, 2009Inventors: Raymond J. Dattwyler, Maria Gomes-Solecki
-
Patent number: 7605248Abstract: Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.Type: GrantFiled: September 26, 2006Date of Patent: October 20, 2009Assignees: Research Foundation of the State University of New York, Brookhaven Sciences Associates, LLCInventors: Raymond J. Dattwyler, Maria J. C. Gomes-Solecki, Benjamin J. Luft, John J. Dunn
-
Patent number: 7582304Abstract: The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing Borrelia. In one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each of Borrelia burgdorferi OspC families A, B, I and K. In another embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each of Borrelia afzelii OspC families A and B.Type: GrantFiled: March 9, 2006Date of Patent: September 1, 2009Assignees: Research Foundation of the State University of New York, Brook Biotechnologies, Inc.Inventors: Raymond J. Dattwyler, Gerald Seinost, Daniel Dykhuizen, Benjamin J. Luft, Maria J. C. Gomes-Solecki
-
Publication number: 20090162875Abstract: The present invention relates, e.g., to an isolated peptide consisting of the sequence MKKDDQIAAAIALRGMA (SEQ ID NO:1) or an active variant thereof, wherein the peptide or active variant can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Also disclosed are linear multimeric peptides that contain the peptide represented by SEQ ID NO:1 as well as one or more additional peptide epitopes from other Borrelia proteins that can also bind specifically to an antibody as above. Compositions and diagnostic kits comprising a peptide of the invention are described, as are diagnostic assays using the peptide(s).Type: ApplicationFiled: November 10, 2008Publication date: June 25, 2009Applicant: Biopeptides CorporationInventors: Raymond J. Dattwyler, Maria J.C. Gomes-Solecki
-
Patent number: 7179448Abstract: Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.Type: GrantFiled: August 3, 2005Date of Patent: February 20, 2007Assignees: Research Foundation of the State of New York, Brookhaven Sciences Associates, LLCInventors: Raymond J. Dattwyler, Maria J. C. Gomes-Solecki, Benjamin J. Luft, John J. Dunn
-
Patent number: 7060281Abstract: The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing Borrelia. In one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each of Borrelia burgdorferi OspC families A, B, I and K. In another embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each of Borrelia afzelii OspC families A and B.Type: GrantFiled: June 19, 2000Date of Patent: June 13, 2006Assignees: Research Foundation of the State University of New York, Brook Biotechnology, Inc.Inventors: Raymond J. Dattwyler, Gerald Seinost, Daniel Dykhuizen, Benjamin J. Luft, Maria J. C. Gomes-Solecki
-
Patent number: 7008625Abstract: Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.Type: GrantFiled: February 18, 2003Date of Patent: March 7, 2006Assignee: Research Foundation of the State University of New YorkInventors: Raymond J. Dattwyler, Maria J. C. Gomes-Solecki, Benjamin J. Luft, John J. Dunn
-
Publication number: 20040033236Abstract: Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.Type: ApplicationFiled: February 18, 2003Publication date: February 19, 2004Applicants: Research Foundation of State University of New York, Brookhaven Sciences Associates, LLCInventors: Raymond J. Dattwyler, Maria J. C. Gomes-Solecki, Benjamin J. Luft, John J. Dunn